Pharmacologic Agents Under Study for Marijuana Withdrawal
Nabilone and nabiximols (synthetic cannabinoids) are the most promising agents for marijuana withdrawal, with evidence showing they reduce withdrawal symptoms and cannabis craving through cannabinoid receptor agonism, functioning similarly to nicotine replacement therapy for tobacco cessation. 1
Primary Cannabinoid Agonist Therapies
Synthetic Cannabinoids (Most Promising)
Nabilone is a synthetic Δ9-THC analogue with demonstrated efficacy in reducing cannabis withdrawal symptoms and craving in persons with cannabis use disorder 1. The mechanism mimics agonist replacement therapy, similar to nicotine replacement for tobacco smokers 1. Nabilone has good oral bioavailability (96%) and a 2-hour elimination half-life, with anxiolytic, anti-emetic, and analgesic properties 1. Common adverse effects include drowsiness, dizziness, vertigo, postural hypotension, and dry mouth 1.
Nabiximols (oromucosal spray containing THC and cannabidiol) can reduce symptoms of cannabis withdrawal syndrome and cannabis craving 1. Evidence suggests these agents work best for patients consuming more than 1.5 g/day of high-THC (>20%) smoked cannabis or more than 20 mg/day of THC oil 1.
Dronabinol shows qualitative evidence of reduced withdrawal symptom intensity and improved retention in treatment (RR=1.27 [1.02; 1.57]) 2, 3. However, abstinence rates at end of treatment were no different from placebo (RR 0.98,95% CI 0.64 to 1.52) 3.
Clinical Application Algorithm for Cannabinoid Agonists
Consider nabilone or nabiximols for patients with cannabis withdrawal symptoms who were consuming: 1
- More than 1.5 g/day smoked cannabis
- More than 300 mg/day CBD-dominant oil
- More than 20 mg/day THC-dominant cannabis oil
- Unknown CBD/THC content more than 2-3 times daily
Do NOT use nabilone or nabiximols for patients consuming less than these thresholds or products with minimal THC content 1
Refer to psychiatry or addiction medicine for suspected cannabis withdrawal syndrome to guide treatment initiation with these agents 1
Secondary Pharmacologic Agents Under Investigation
Anticonvulsants
Gabapentin reduced cannabis cravings (d=-2.42 [-3.53; -1.32]) in network meta-analysis 2. The evidence base remains weak but warrants further investigation 3.
Topiramate reduced cannabis use relative to placebo (d=-3.80 [-7.06; -0.54]) but worsened treatment retention (RR=0.62 [0.42; 0.91]) and caused significantly more adverse events (RR=9.10 [1.27; 65.11]) and dropouts due to adverse events 2. This limits clinical utility despite efficacy for reducing use.
Glutamatergic Agents
N-acetylcysteine shows promise in some studies but demonstrated no difference in abstinence rates at end of treatment compared to placebo, with moderate-quality evidence 3. Adverse effects were comparable to placebo (RR 0.94,95% CI 0.71 to 1.23) 3. The evidence base remains weak 3.
Fatty Acid Amide Hydrolase (FAAH) Inhibitors
FAAH inhibitors reduced cannabis use relative to placebo (d=-2.30 [-4.75; 0.15]) in network meta-analysis 2. These agents target endocannabinoid tone and represent an emerging investigational approach 4.
Other Agents with Limited Evidence
Buspirone showed no difference in abstinence compared to placebo but caused more adverse events (RR=1.14 [1.00; 1.29]) 2, 3.
SSRI antidepressants (fluoxetine, others) and mixed action antidepressants (venlafaxine, bupropion) are probably of little value in treating cannabis dependence, with no difference in abstinence rates and, in the case of venlafaxine, increased adverse events (RR=1.78 [1.40; 2.26]) 2, 3.
Vilazodone worsened craving severity (d=1.69 [0.71; 2.66]) 2.
Oxytocin and atomoxetine have insufficient evidence for estimates of effectiveness 3.
Clinical Context and Withdrawal Recognition
Cannabis withdrawal syndrome occurs in approximately 50% of regular and dependent cannabis users after cessation, with symptoms including irritability, anger, anxiety, insomnia, decreased appetite, restlessness, altered mood, and physical symptoms (abdominal pain, tremors, sweating, fever, chills, headache) 1, 5. Symptoms typically occur 24-72 hours after cessation, peak in the first week, and last 1-2 weeks 1. The Cannabis Withdrawal Scale can be used for assessment 1.
Critical Limitations
Despite promising signals, there is incomplete evidence for all pharmacotherapies investigated, with most evidence rated as low to very low quality 3. No medications are currently FDA-approved specifically for cannabis withdrawal or cannabis use disorder 6, 7, 4. Psychosocial interventions should remain first-line treatment given the limitations in available pharmacological evidence 2.
The most appropriate dosages for cannabinoid agonist interventions are not known, and expert guidance from clinicians familiar with prescribing cannabis, nabilone, or nabiximols should be sought (pain specialists, psychiatrists, addiction medicine specialists) 1.